Lookup NU author(s): Dr Thomas Huegle,
Professor Jaap Van Laar
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Haematopoietic stem cell transplantation (HSCT) has evolved from an experimental concept to an effective treatment option for severe autoimmune diseases and has a unique ability to restore immune regulation. It is a complex multistep procedure involving the administration of high doses of immunosuppressive medication and transplantation of stem cells. Most HSCT procedures in autoimmune disease have involved autologous stem cells. In the case of allogeneic transplantation, stem cells are derived from peripheral blood or bone marrow of a healthy HLA-matched donor. Allogeneic HSCT has curative potential based on studies in experimental models of autoimmune disease, case reports, and a registry analysis but carries significant risks of rejection and graft-versushost disease. Unless these risks become manageable, allogeneic HSCT should be offered only if all alternative treatment options have failed, if a patient has a suitable donor, and if a patient still has a chance to benefit significantly from the procedure. © 2010 Medicine Reports Ltd.
Author(s): Hügle T, Van Laar J
Publication type: Review
Publication status: Published
Journal: F1000 Medicine Reports
Print publication date: 25/03/2010
ISSN (print): 1757-5931